Clinical Research Papers:
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis
Metrics: PDF 256 views | HTML 216 views | ?
Nan Chen1,*, Shuai Liu1,*, Lin Huang1,*, Wanling Li1, Wenhao Yang1, Tianxin Cong1, Lin Ding1 and Meng Qiu1,2
1 West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
2 Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Guoxue Alley, Chengdu, China
* These authors have contributed equally to this work
Meng Qiu, email:
Keywords: inflammation, malignant pleural mesothelioma, neutrophil-to-lymphocyte ratio, prognosis, meta-analysis
Received: August 01, 2016 Accepted: January 30, 2017 Published: February 16, 2017
Systemic inflammation responses can be reflected by peripheral blood count and combine index like the neutrophil-to-lymphocyte (NLR). The NLR has been reported to be a poor prognostic indicator in cancer recently. However, the prognostic effect of the NLR in patients with malignant pleural mesothelioma (MPM) still unclear yet. We conducted this meta-analysis aiming to evaluate the pooled value of NLR in prognosis as well as clinical characteristics in malignant pleural mesothelioma. A total of 11 studies with 1533 patients were included in this meta-analysis, in which 10 studies investigated the prognosis role of NLR using hazard ratio (HR) and 95% confidence intervals (95% CI). The elevated NLR was detected to be associated with a poor overall survival (OS)(HR=1.48, 95%CI=1.16-1.89, P < 0.001). The significant prognostic roles of NLR were also indicated in subgroup analyses. NLR level was also associated with histology instead of gender, stage or performance status (PS) score. These findings suggested that the elevated NLR could be a potential prognostic factor for malignant pleural mesothelioma patients and might be associated with histology as an efficient clinical index to stratify patients.
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.